721. Deputy Seán Kyne asked the Minister for Health the action the HSE and HPRA are taking on the current supply shortage of budesonide orodispersible tablets in the State. [70677/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions under the heading Medicinal Products.
1,228 questions match, newest first.
723. Deputy Seán Kyne asked the Minister for Health the current status of the HSE's full health technology assessment of budesonide orodispersible tablets (Jorveza, NCPE HTA ID 24014) for eosinophilic oesophagitis, commissioned on 25 June 2024; the reason no outcome has been published in over two years; and the expected date of a reimbursement decision. [70675/26]
166. Deputy Denise Mitchell asked the Minister for Health if consideration is currently being given to the use of cannabis-based medicines for chronic pain relief, specifically in relation to endometriosis. [68992/26]
171. Deputy Erin McGreehan asked the Minister for Health the amount of the €30 million allocated in Budget 2026 for new and innovative medicines that has been spent to date; the number and names of medicines approved for reimbursement using this allocation; the number of patients who have benefited; the amount remaining unspent; and if she will make a statement on the matter. [69130/26]
175. Deputy Cathal Crowe asked the Minister for Health if a medication (details supplied) will be included as a reimbursable medicine under the drugs payment scheme. [69120/26]
179. Deputy Martin Kenny asked the Minister for Health the reason a persons application (details supplied) for a CGM monitor has been denied. [69148/26]
186. Deputy Pádraig O'Sullivan asked the Minister for Health if a drug (details supplied) is currently available for reimbursement to eligible patients in Ireland; the current status and outcome of its assessment for reimbursement; whether Irish residents receiving clinically indicated cancer treatment in Northern Ireland can have the cost of the drug covered by the State where the medicine is not reimbursed in Irela…
779. Deputy John Paul O'Shea asked the Minister for Health To the current status of HSE pricing and reimbursement negotiations for a drug (details supplied); the expected timeline for concluding these negotiations and making the medication available under the drugs payment scheme; and the steps being taken to ensure equitable access to menopause treatment for women who cannot take HRT for medical reasons, including s…
800. Deputy George Lawlor asked the Minister for Health to clarify the arrangements governing the provision of medication blister packs, also known as monitored dosage systems, by community pharmacies; the circumstances in which medical card holders may receive them without an additional charge where clinically required; whether people living with dementia and other patients who face medication-safety risks are cover…
807. Deputy Pearse Doherty asked the Minister for Health if a drug (details supplied) will be made available under the drug payment scheme for patients who cannot take HRT as a result of a cancer diagnosis; and the current status of the application. [68721/26]
836. Deputy Naoise Ó Muirí asked the Minister for Health her plans to expand the medical cannabis access programme to include chronic pain conditions, including endometriosis; and if she will make a statement on the matter. [68856/26]
878. Deputy Jennifer Whitmore asked the Minister for Health if she will consider adding Veoza (fezolinetant) to the drug scheme list, to ensure women who cannot use HRT, for example due to cancer treatment, have access to an affordable non hormonal treatment for severe menopausal symptoms; and if she will make a statement on the matter. [68865/26]
883. Deputy Mary Lou McDonald asked the Minister for Health if the Government is currently reviewing the reimbursement status of testosterone products prescribed to women. [68963/26]
884. Deputy Mary Lou McDonald asked the Minister for Health the reason female-specific testosterone formulations are not currently included in the free HRT arrangements. [68964/26]
885. Deputy Mary Lou McDonald asked the Minister for Health if she will consider adding appropriate female testosterone formulations to the reimbursement list in the treatment of menopause and perimenopause. [68966/26]
886. Deputy Mary Lou McDonald asked the Minister for Health the steps being taken to ensure that women requiring testosterone are able to access an appropriate formulation without having to pay privately. [68967/26]
893. Deputy Cian O'Callaghan asked the Minister for Health if she supports expanding the medical cannabis access programme, MCAP, to ensure that more people affected by severe chronic illnesses can access cannabis in circumstances where other treatments have failed to relieve symptoms; and if she supports expanding MCAP to support those who have been impacted by endometriosis. [68953/26]
431. Deputy Robert Troy asked the Minister for Health if she will clarify the roll out of insulin pumps at the diabetic clinic based at the midlands regional hospital Mullingar; if the clinic currently has the capacity to roll out pumps; and the steps being taken to provide the necessary resources. [67693/26]
473. Deputy Pádraig Mac Lochlainn asked the Minister for Health to advise on matter raised in correspondence (details supplied). [67884/26]
156. Deputy Paul Murphy asked the Minister for Health the status of a medication (details supplied) for the treatment of Phenylketonuria (PKU) in Ireland. [67252/26]
204. Deputy David Cullinane asked the Minister for Health the number of medicines which entered the HSE reimbursement process in each year 2021 to 2025 and to date in 2026; the number which received a final reimbursement decision; the average, median and longest time spent at each stage from reimbursement application and pharmacoeconomic assessment to final decision; the number and duration of clock stops; the number…
525. Deputy Shónagh Ní Raghallaigh asked the Minister for Health if her Department will assess a medication (details supplied) for availability and reimbursement here as a viable treatment option for phenylketonuria; and if she will make a statement on the matter. [66346/26]
554. Deputy Ken O'Flynn asked the Minister for Health whether the HSE monitored the substitution between nebulised products (details supplied) during the supply shortages affecting these medicines in 2025 and 2026; and the steps taken to ensure continuity of treatment for affected patients. [66545/26]
555. Deputy Ken O'Flynn asked the Minister for Health the data the HSE holds on patients who were unable to access a reimbursed nebulised bronchodilator during recent supply shortages and who consequently purchased an alternative product privately at their own expense; and, if no such data is held, to state that plainly. [66544/26]
556. Deputy Ken O'Flynn asked the Minister for Health whether the reimbursement of alternative nebulised bronchodilator products during periods of shortage, including under the Discretionary Hardship Arrangements, is applied consistently across all health regions; and to provide the number of such claims processed in the period January to June 2026, by health region. [66543/26]